The average hospital in the 340B program charges commercial insurers more than non-340B hospitals, according to a new report, which [...] …
Category: Pharma Industry
GlaxoSmithKline owes refunds to 340B providers, according to a notice posted on the Health Resources and Services Administration’s Office of [...] …
Pharmaceutical giant Eli Lilly this week announced it would reinstate tighter 340B contract pharmacy restrictions for all covered entity types. [...] …
An influential drug industry trade group recently urged a federal judge to rule on its suit against Louisiana’s 340B contract [...] …
The Arkansas Insurance Department (AID) recently asked a federal district judge to dismiss Novo Nordisk’s lawsuit that challenges Arkansas’ state [...] …
Organon, a Merck spinoff with a focus on women’s health, yesterday became the sixth drugmaker to loosen or end its [...] …
Lobbying on 340B issues in 2023 remains on track for a record-breaking year, according to recently released congressional lobbying reports. [...] …
Enrollment in the 340B program was linked to diminished spending on charity care, according to preliminary findings from an ongoing [...] …
Generic and biosimilar drugmaker Sandoz today became the 28th pharmaceutical company to place conditions on 340B pricing involving drug shipments [...] …
GlaxoSmithKline (GSK) today became the fifth drug manufacturer to loosen or end its 340B contract pharmacy restrictions in Arkansas and [...] …